 | ||||||||
| "anti diabetes" | ||||||||
| NEWS | ||||||||
Implications Of Novo Nordisk's Positive CV Outcome Data From LEADER Study DPP-IV would lose market share- Currently DPP-IV drugs take about 8% volume share of the anti-diabetes market as against 2% for the GLP-1 class.
| ||||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.